Understanding the possible side effects of Idvynso and mastering the correct countermeasures are key to ensuring safe and smooth treatment.

I. Watch for serious adverse reactions that require immediate medical attention

1. Severe skin reactions

This is a serious adverse reaction highlighted in the Idvynso prescribing information. If any of the following occur, stop the drug immediately and seek medical help:

(1) Rash accompanied by pain, especially when the rash spreads to mucous membranes such as the mouth or eyes.

(2) Rapidly progressing rash, or rash with blisters or skin peeling.

(3) Rash occurring together with fever, swollen lymph nodes, facial swelling, or general malaise.

(4) These may be signs of Stevens-Johnson syndrome or drug reaction with eosinophilia and systemic symptoms (DRESS).

2. Severe hematologic reactions

In clinical trials, some patients developed severe immune thrombocytopenia after treatment. Typical manifestations include:

(1) Unexplained bruising or hematomas under the skin.

(2) Pinpoint bleeding spots (petechiae) on the skin.

(3) Blood in the urine.

(4) If any of these signs appear, contact your doctor immediately for evaluation.

II. Understand and manage common adverse reactions

1. Gastrointestinal reactions

(1) Diarrhea: one of the more commonly reported reactions. Maintain adequate fluid intake and avoid greasy or spicy foods.

(2) Abdominal bloating: some people may experience gas or distension. Eating smaller, more frequent meals and taking a gentle walk after meals may help relieve it.

2. Neurologic and systemic reactions

(1) Dizziness and headache: may occur early in treatment. Avoid standing up suddenly or engaging in activities that require high concentration.

(2) Fatigue: some people may feel tired. Ensure adequate rest and schedule activities for times when you have the most energy.

3. Other parameters to monitor

Weight gain: reported by some users. Maintain a balanced diet and regular exercise during treatment, and monitor weight changes periodically.

III. Comprehensive considerations for long‑term health and medication safety

1. Special population precautions

(1) Renal function: not recommended for patients with severe renal impairment. Your doctor will monitor renal function parameters before and during treatment.

(2) Hepatic function: not recommended for patients with severe hepatic impairment. Particular caution is needed in patients with coexisting hepatitis B, as this drug is not effective against hepatitis B virus; close monitoring is required during treatment switches or therapy.

(3) Elderly patients: clinical trials included some elderly patients, and no overall differences were observed, but individual elderly patients may be more sensitive.

2. Drug‑interaction risks

As a complete regimen, Idvynso should not be co‑administered with other antiretroviral drugs.

(1) Strictly contraindicated: co‑administration with strong CYP3A enzyme inducers, lamivudine, or emtricitabine is prohibited, as it will significantly reduce efficacy.

(2) Dose adjustment required: when co‑administered with rifabutin, an additional tablet of doravirine should be taken approximately 12 hours after the Idvynso dose.

(3) Not recommended: avoid co‑administration with certain nucleoside antimetabolites or adenosine deaminase inhibitors (e.g., pentostatin), which may affect efficacy or increase toxicity.